Gregory J. Nadolski, MD

MD
Hospital of the University of PA, United States

Presentation(s):

• The Instylla HES Hypervascular Tumor Study: A Prospective, Randomized, Multicenter Study of a Liquid Embolic for Treatment of Hypervascular Tumors

  Sunday, March 30, 2025
  4:12 PM – 4:21 PM CT

• 70 - Utility of Alpha-Fetoprotein (AFP) monitoring after Y-90 radioembolization of hepatocellular carcinoma in non-AFP producers

  Monday, March 31, 2025
  12:10 PM – 1:10 PM CT

• 82 - Drain for life? Outcomes of Percutaneous Drainage of Malignancy-Associated Abscesses

  Monday, March 31, 2025
  12:10 PM – 1:10 PM CT

• A Single Institutional Experience with Pulsed Electric Field Ablation in the Treatment of Patients with Localized and Metastatic Cancer

  Tuesday, April 1, 2025
  3:00 PM – 3:09 PM CT

• Lipiodol Deposition in NET Liver Metastases during TACE using Pressure-Enabled versus Endhole Catheters: Pilot Data from a Randomized, Internally-Controlled Trial

  Tuesday, April 1, 2025
  3:54 PM – 4:03 PM CT

• Pilot Randomized Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients Awaiting Transplantation

  Tuesday, April 1, 2025
  4:12 PM – 4:21 PM CT

• Premedication with NK-1 antagonists and COX-2 inhibitors improves same day discharge rates following chemoembolization for hepatocellular carcinoma and neuroendocrine liver metastasis

  Tuesday, April 1, 2025
  4:21 PM – 4:30 PM CT

• The Effects of a Standardized Enhanced Recovery After Surgery (ERAS) Pain Management Protocol for Patients Undergoing a Uterine Fibroid Embolization (UFE)

  Tuesday, April 1, 2025
  3:09 PM – 3:18 PM CT